Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2020

View Archived Issues

AD and HHV: Still a mystery

Glial cells contribute to brain control of aging

New phase III trial evaluates MK-6482 in advanced renal cell carcinoma

Genetic removal of mast cell Tph1 protects mice from developing obesity and insulin resistance

FDA approves Dificid for C. difficile infection in children age 6 months and older

FDA clears NeoImmuneTech's IND to study NT-I7 plus pembrolizumab in advanced solid tumors

Otsuka reports promising topline data from Japanese trials of fremanezumab in migraine

LNA-anti-miR-150 ameliorates FSGS in vivo

Targeting SK1 overcomes resistance to immune checkpoint inhibitors in melanoma

Retinoic X receptor as therapeutic target for poststroke recovery

Vallon Pharmaceuitcals presents results on manipulated dextroamphetamine sulfate

New hydroxyacid oxidase 1 inhibitors discovered at Orfan Biotech

Gilead describes new IDO-1 inhibitors

Novartis Inflammasome Research describes new NLRP3 inflammasome inhibitors

New CRLF2 ligands identified at Korea University Research and Business Foundation

GeoVax and BravoVax sign letter of intent to codevelop 2019-nCoV coronavirus vaccine

FDA approves Trijardy XR for type 2 diabetes

miR-3064-5p found to have prognostic value in HCC

PULSAR trial of sotatercept in pulmonary arterial hypertension meets primary endpoint

Sichuan Kelun-Biotech Biopharmaceutical discloses RORC agonists

FDA clears INDs for Surface Oncology's antibody candidates SRF-617 and SRF-388

Study suggests direct amino acid toxicity could account for caloric restriction benefits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...